Rituximab biosimilar - Celltrion

Drug Profile

Rituximab biosimilar - Celltrion

Alternative Names: Blitzima; CT-P10; Ritemvia; Truxima; Tuxella

Latest Information Update: 22 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Celltrion
  • Developer Celltrion; Teva Pharmaceutical Industries
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Follicular lymphoma; Non-Hodgkin's lymphoma; Rheumatoid arthritis; Wegener's granulomatosis
  • Registered Diffuse large B cell lymphoma; Microscopic polyangiitis

Most Recent Events

  • 29 Jun 2017 Launched for Chronic lymphocytic leukaemia in South Korea (IV)
  • 29 Jun 2017 Launched for Chronic lymphocytic leukaemia in United Kingdom, Spain, Netherlands, Germany (IV)
  • 29 Jun 2017 Launched for Non-Hodgkin's lymphoma in South Korea (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top